Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Sep;40(9):2047–2053. doi: 10.1128/aac.40.9.2047

Drug effects on intracellular mycobacteria determined by mass spectrometric analysis of the Na(+)-to-K+ ratios of individual bacterial organisms.

M Wiese 1, U Seydel 1
PMCID: PMC163471  PMID: 8878579

Abstract

The successful establishment of a drug screening system for intracellular cultivable and noncultivable mycobacteria based on the mass spectrometric determination of bacterial viability is described. To compare drug efficacies on intra- and extracellular mycobacteria, the mycobacteria were subjected to drug treatment either after phagocytosis by the mouse macrophage cell line RAW 264.7 or in cell-free medium. After reisolation, their viability was monitored by analyzing the intrabacterial sodium-to-potassium ratios for a limited number of individual organisms. This approach offers a reliable and quick tool for monitoring the influence of intracellular growth and of additional permeation barriers on intracellular drug efficacy and will thus provide useful information for the rational development and testing of optimized antimycobacterial drugs. In particular, the methodology is applicable to the noncultivable species Mycobacterium leprae, because the mass spectrometric analysis of the intrabacterial sodium-to-potassium ratio allows the determination of bacterial viability independent from their ability to multiply in vitro. Because of the improved metabolic activity of intracellularly growing M. leprae compared with that of extracellularly growing M. leprae, the spectrum of antileprosy drugs that can be tested in vitro could even be extended to those interfering with DNA replication and cell division.

Full Text

The Full Text of this article is available as a PDF (300.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abou-Zeid C., Garbe T., Lathigra R., Wiker H. G., Harboe M., Rook G. A., Young D. B. Genetic and immunological analysis of Mycobacterium tuberculosis fibronectin-binding proteins. Infect Immun. 1991 Aug;59(8):2712–2718. doi: 10.1128/iai.59.8.2712-2718.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bloom B. R., Murray C. J. Tuberculosis: commentary on a reemergent killer. Science. 1992 Aug 21;257(5073):1055–1064. doi: 10.1126/science.257.5073.1055. [DOI] [PubMed] [Google Scholar]
  3. Cao C. X., Silverstein S. C., Neu H. C., Steinberg T. H. J774 macrophages secrete antibiotics via organic anion transporters. J Infect Dis. 1992 Feb;165(2):322–328. doi: 10.1093/infdis/165.2.322. [DOI] [PubMed] [Google Scholar]
  4. Cavalieri S. J., Biehle J. R., Sanders W. E., Jr Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995 Jul;39(7):1542–1545. doi: 10.1128/aac.39.7.1542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Crowle A. J., Elkins N., May M. H. Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium, and rifampin against M. tuberculosis in cultured human macrophages. Am Rev Respir Dis. 1988 May;137(5):1141–1146. doi: 10.1164/ajrccm/137.5.1141. [DOI] [PubMed] [Google Scholar]
  6. Crowle A. J., Poche P. Inhibition by normal human serum of Mycobacterium avium multiplication in cultured human macrophages. Infect Immun. 1989 Apr;57(4):1332–1335. doi: 10.1128/iai.57.4.1332-1335.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dellagostin O. A., Esposito G., Eales L. J., Dale J. W., McFadden J. Activity of mycobacterial promoters during intracellular and extracellular growth. Microbiology. 1995 Aug;141(Pt 8):1785–1792. doi: 10.1099/13500872-141-8-1785. [DOI] [PubMed] [Google Scholar]
  8. Dhople A. M., Storrs E. E. Adenosine triphosphate content of Mycobacterium leprae: effect of purification procedures. Int J Lepr Other Mycobact Dis. 1982 Mar;50(1):83–89. [PubMed] [Google Scholar]
  9. Dietz M., Haas M., Lindner B., Dhople A. M., Tebebe Y. B., Seydel U. Intrabacterial sodium-to-potassium ratios and ATP contents of Mycobacterium leprae from ofloxacin-treated patients. Int J Lepr Other Mycobact Dis. 1991 Dec;59(4):548–557. [PubMed] [Google Scholar]
  10. Gottesman M. M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385–427. doi: 10.1146/annurev.bi.62.070193.002125. [DOI] [PubMed] [Google Scholar]
  11. Haas M., Lindner B., Dietz M., Tebebe Y. B., Seydel U. Determination of in vivo and in vitro drug effects of mycobacteria from the mass spectrometric analysis of single organisms. Int J Lepr Other Mycobact Dis. 1991 Jun;59(2):262–270. [PubMed] [Google Scholar]
  12. Johnson J. D., Hand W. L., Francis J. B., King-Thompson N., Corwin R. W. Antibiotic uptake by alveolar macrophages. J Lab Clin Med. 1980 Mar;95(3):429–439. [PubMed] [Google Scholar]
  13. KUBICA G. P., DYE W. E., COHN M. L., MIDDLEBROOK G. Sputum digestion and decontamination with N-acetyl-L-cysteine-sodium hydroxide for culture of mycobacteria. Am Rev Respir Dis. 1963 May;87:775–779. doi: 10.1164/arrd.1963.87.5.775. [DOI] [PubMed] [Google Scholar]
  14. Lindner B., Seydel U. Mass spectrometric analysis of drug-induced changes in Na+ and K+ contents of single bacterial cells. J Gen Microbiol. 1983 Jan;129(1):51–55. doi: 10.1099/00221287-129-1-51. [DOI] [PubMed] [Google Scholar]
  15. Mor N. Intracellular location of Mycobacterium leprae in macrophages of normal and immune-deficient mice and effect of rifampin. Infect Immun. 1983 Nov;42(2):802–811. doi: 10.1128/iai.42.2.802-811.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mor N., Simon B., Mezo N., Heifets L. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob Agents Chemother. 1995 Sep;39(9):2073–2077. doi: 10.1128/aac.39.9.2073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Myrvik Q. N., Leake E. S., Wright M. J. Disruption of phagosomal membranes of normal alveolar macrophages by the H37Rv strain of Mycobacterium tuberculosis. A correlate of virulence. Am Rev Respir Dis. 1984 Feb;129(2):322–328. [PubMed] [Google Scholar]
  18. Ortalo-Magné A., Dupont M. A., Lemassu A., Andersen A. B., Gounon P., Daffé M. Molecular composition of the outermost capsular material of the tubercle bacillus. Microbiology. 1995 Jul;141(Pt 7):1609–1620. doi: 10.1099/13500872-141-7-1609. [DOI] [PubMed] [Google Scholar]
  19. Plum G., Clark-Curtiss J. E. Induction of Mycobacterium avium gene expression following phagocytosis by human macrophages. Infect Immun. 1994 Feb;62(2):476–483. doi: 10.1128/iai.62.2.476-483.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Rastogi N., Barrow W. W. Cell envelope constituents and the multifaceted nature of Mycobacterium avium pathogenicity and drug resistance. Res Microbiol. 1994 Mar-Apr;145(3):243–261. doi: 10.1016/0923-2508(94)90025-6. [DOI] [PubMed] [Google Scholar]
  21. Rastogi N., Goh K. S., Bryskier A. Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex. Antimicrob Agents Chemother. 1994 Jun;38(6):1433–1438. doi: 10.1128/aac.38.6.1433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rastogi N., Labrousse V., Goh K. S., De Sousa J. P. Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages. Antimicrob Agents Chemother. 1991 Dec;35(12):2473–2480. doi: 10.1128/aac.35.12.2473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Reddy V. M., Nadadhur G., Daneluzzi D., Dimova V., Gangadharam P. R. Antimycobacterial activity of a new rifamycin derivative, 3-(4-cinnamylpiperazinyl iminomethyl) rifamycin SV (T9). Antimicrob Agents Chemother. 1995 Oct;39(10):2320–2324. doi: 10.1128/aac.39.10.2320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Schorey J. S., Li Q., McCourt D. W., Bong-Mastek M., Clark-Curtiss J. E., Ratliff T. L., Brown E. J. A Mycobacterium leprae gene encoding a fibronectin binding protein is used for efficient invasion of epithelial cells and Schwann cells. Infect Immun. 1995 Jul;63(7):2652–2657. doi: 10.1128/iai.63.7.2652-2657.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Seydel U., Lindner B., Dhople A. M. Results from cation and mass fingerprint analysis of single cells and from ATP measurements of M. leprae for drug sensitivity testing: a comparison. Int J Lepr Other Mycobact Dis. 1985 Sep;53(3):365–372. [PubMed] [Google Scholar]
  26. Skinner P. S., Furney S. K., Kleinert D. A., Orme I. M. Comparison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995 Mar;39(3):750–753. doi: 10.1128/AAC.39.3.750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Utrup L. J., Moore T. D., Actor P., Poupard J. A. Susceptibilities of nontuberculosis mycobacterial species to amoxicillin-clavulanic acid alone and in combination with antimycobacterial agents. Antimicrob Agents Chemother. 1995 Jul;39(7):1454–1457. doi: 10.1128/aac.39.7.1454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Warwick-Davies J., Dhillon J., O'Brien L., Andrew P. W., Lowrie D. B. Apparent killing of Mycobacterium tuberculosis by cytokine-activated human monocytes can be an artefact of a cytotoxic effect on the monocytes. Clin Exp Immunol. 1994 May;96(2):214–217. doi: 10.1111/j.1365-2249.1994.tb06544.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES